Skip to main content
Have a personal or library account? Click to login
Triple negative breast cancer - prognostic factors and survival Cover

Triple negative breast cancer - prognostic factors and survival

Radiology and Oncology
Volume 45 (2011): Issue 1 (March 2011)
By: ,  ,  ,   and    
Open Access
|Dec 2010
References

References

  1. Gluz O, Liedtke C, Gottschalk N, Pustzai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions.2009;: 1913-27.
    Open DOISearch in Google Scholar
  2. Podkrajšek M, Žgajnar J, Hočevar M. What is the most common mammographic appearance of T1a and T1b inasive breast cancer?2008;: 173-80.
    Open DOISearch in Google Scholar
  3. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: Clinical and prognostic implications.2009;: 27-40.
    Open DOISearch in Google Scholar
  4. Anders KC, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.2009;: S73-81.
    Open DOISearch in Google Scholar
  5. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.1991;: 403-10
    Open DOISearch in Google Scholar
  6. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options.2007;: 235-44.
    Open DOISearch in Google Scholar
  7. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway KS, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.2006;: 2492-502.
    Open DOISearch in Google Scholar
  8. Debevec L, Jeric T, Kovac V, Bitenc M, Sok M. Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006.2009;: 47-53.
    Open DOISearch in Google Scholar
  9. Tian XS, Cong MH, Zhou WH, Zhu J, Chen YZ, Liu Q. Clinicopathologic and prognostic characteristics of triple-negative breast cancer.;: 610-4.
    Search in Google Scholar
  10. Shibuta K, Ueo H, Furusawa H, Komaki K, Rai Y, Sagar Y, et al. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4266 Japanese women with breast cancer.2010; Jun 23. [Epub ahead of print]. DOI: 10.1007/s12282-010-0209-6.
    Open DOISearch in Google Scholar
  11. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer?2008;: 303-8.
    Open DOISearch in Google Scholar
  12. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence.2007; 13: 4429-34.
    Open DOISearch in Google Scholar
  13. Plesnicar A, Golicnik M, Fazarinc IK, Kralj B, Kovac V, Plesnicar BK. Attitudes of midwifery students towards teaching breast-self examination.2010;: 52-6.
    Open DOISearch in Google Scholar
  14. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, et al. Invasive ductal carcinoma of the breast with "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.2009;: 317-28.
    Open DOISearch in Google Scholar
  15. Liedke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.2008;:1275-81.
    Open DOISearch in Google Scholar
  16. Lin NU, Vanderplas A, Hughes ME, Theriault R L, Edge SB, Wong Y, et al. Clinopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). [Abstract].2009;Abstract 543.
    Open DOISearch in Google Scholar
  17. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, et al. Prognostic impact of clinicopathological parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.2007;: 203.
    Open DOISearch in Google Scholar
  18. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.2007;: 2329-34.
    Open DOISearch in Google Scholar
  19. Tutt A, Robson M, Garber JE, Domchek S. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. [Abstract].2009;803s.
    Open DOISearch in Google Scholar
  20. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. [Abstract].;793s.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10019-010-0054-4 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 46 - 52
Published on: Dec 31, 2010
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
triple negative breast cancer,
prognostic factors,
treatment outcome
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2010 Tanja Ovcaricek, Snjezana Frkovic, Erika Matos, Barbara Mozina, Simona Borstnar, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 45 (2011): Issue 1 (March 2011)
Previous article
Next article